1-3 of 3
Angela G. Fleischman
Close
Sort by
Journal Articles

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Clinical Trials & Observations
Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark L. Heaney, Casey O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4282–4291.
https://doi.org/10.1182/bloodadvances.2020002662
Published: 2020
Includes: Supplemental data
Journal Articles

N -acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm

Brianna M. Craver, Gajalakshmi Ramanathan, Summer Hoang, Xinyue Chang, Laura F. Mendez Luque, Stefan Brooks, Hew Yeng Lai, Angela G. Fleischman
Journal: Blood Advances
Blood Adv (2020) 4 (2): 312–321.
https://doi.org/10.1182/bloodadvances.2019000967
Published: 2020
Includes: Supplemental data
Journal Articles

Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm

Clinical Trials & Observations
Hew Yeng Lai, Stefan A. Brooks, Brianna M. Craver, Sarah J. Morse, Thanh Kim Nguyen, Nahideh Haghighi, Michael R. Garbati, Angela G. Fleischman
Journal: Blood Advances
Blood Adv (2019) 3 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2018026450
Published: 2019
Includes: Supplemental data